Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
The Shasta system and Shasta Whole-Genome Amplification (WGA) Kit dramatically increase throughput for WGA by processing up to 1,500 cells per run
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
